ByronJHoogwerfMD

PubMed

• 3 citations
  Statins may increase diabetes, but benefit still outweighs risk.
  Byron J Hoogwerf> ;Cleveland Clinic Journal of Medicine. 2023 Jan 3
• 8 citations
  Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus.
  Janet B. McGill, Daniel J. Weiss, Marshall Grant, Marisa C. Jones, David M. Kendall, Byron J. Hoogwerf> ;Journal of Diabetes. 2021 Feb 1
• 8 citations
  Results of a 24-Week Trial of Technosphere Insulin Versus Insulin Aspart in Type 2 Diabetes
  Byron J. Hoogwerf, Kevin M. Pantalone, Marina Basina, Marisa C. Jones, Marshall Grant, David M. Kendall> ;Endocrine Practice. 2021 Jan 1
• 9 citations
  Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus
  Philip Levin, Byron J. Hoogwerf, Janet K. Snell-Bergeon, Tim Vigers, Laura Pyle, Lee A. Bromberger> ;Endocrine Practice. 2020 Dec 14
• 2 citations
  Hypoglycemia in Older Patients
  Byron J. Hoogwerf> ;Clinics in Geriatric Medicine. 2020 Aug 1
• 1 citations
  Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race.
  Byron J. Hoogwerf, Michele Mackenzie, Whitney Sealls, Jeanine M. Cordova, Pranav K. Gandhi> ;Diabetes Therapy. 2020 May 27
• 3 citations
  Type of diabetes mellitus: Does it matter to the clinician?
  Byron J. Hoogwerf> ;Cleveland Clinic Journal of Medicine. 2020 Feb 1
• 11 citations
  The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro
  Sreekumar G. Pillai, Suman Duvvuru, Pallav Bhatnagar, Wendra M. Foster, M Farmen, Sudha S. Shankar, C Harris, Edward J. Bastyr, Byron J. Hoogwerf, Axel Haupt> ;The Pharmacogenomics Journal. 2018 May 22
• 2 citations
  Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
  Arun J. Sanyal, Kenneth Cusi, Mark L. Hartman, Shuyu Zhang, Edward J. Bastyr, Juliana M. Bue-Valleskey, Annette M. Chang, Axel Haupt, Scott J. Jacober, Robert J. Konra...> ;Journal of Investigative Medicine. 2018 Mar 1
• 11 citations
  Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-d...
  Carlos Alatorre, Byron J. Hoogwerf, Mark A. Deeg, David R. Nelson, Theresa Hunter, Wee Teck Ng, Mark David Rekhter> ;Current Medical Research and Opinion. 2018 Feb 1
• 22 citations
  Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes.
  Jason C. Simeone, Jay P. Bae, Byron J. Hoogwerf, Qian Li, Axel Haupt, Ayad K. Ali, Marilyn K. Boardman, Beth L. Nordstrom> ;Clinical Epidemiology. 2017 Dec 14
• 3 citations
  Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetes.
  Margery A. Connelly, James D. Otvos, Qianyi Zhang, Shuyu Zhang, Caryl J. Antalis, Annette M. Chang, Byron J. Hoogwerf> ;Biomarkers in Medicine. 2017 Nov 1
• 11 citations
  Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinica...
  Jay P. Bae, Ran Duan, Haoda Fu, Byron J. Hoogwerf> ;Clinical Therapeutics. 2017 Sep 1
• 7 citations
  The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
  Trevor J. Orchard, Bertrand Cariou, Margery A. Connelly, James D. Otvos, Shuyu Zhang, Caryl J. Antalis, Tibor Ivanyi, Byron J. Hoogwerf> ;Cardiovascular Diabetology. 2017 Jun 6
• 118 citations
  Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes
  Kenneth Cusi, Arun J. Sanyal, Shuyu Zhang, Mark L. Hartman, Juliana M. Bue-Valleskey, Byron J. Hoogwerf, Axel Haupt> ;Diabetes, Obesity & Metabolism. 2017 Nov 1
• 16 citations
  Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
  Henry N. Ginsberg, Bertrand Cariou, Trevor J. Orchard, Lei Chen, Junxiang Luo, Edward J. Bastyr, Juliana M. Bue-Valleskey, Annette M. Chang, Tibor Ivanyi, Scott J. Jac...> ;Diabetes, Obesity & Metabolism. 2016 Nov 1
• 28 citations
  Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
  Kenneth Cusi, Arun J. Sanyal, Shuyu Zhang, Byron J. Hoogwerf, Annette M. Chang, Scott J. Jacober, Juliana M. Bue-Valleskey, A. N. Higdon, Edward J. Bastyr, Axel Haupt,...> ;Diabetes, Obesity & Metabolism. 2016 Oct 10
• 6 citations
  Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study
  Satish K. Garg, J.-L. Selam, A. Bhargava, Nanette C. Schloot, Junxiang Luo, Qianyi Zhang, Jennie G. Jacobson, Byron J. Hoogwerf> ;Diabetes, Obesity & Metabolism. 2016 Oct 10
• 8 citations
  Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications
  Byron J. Hoogwerf, David H. Manner, Haoda Fu, Elena Moscarelli, Brenda Gaydos, Robert J. Heine> ;Diabetes Care. 2016 Aug 1
• 9 citations
  Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.
  Byron J. Hoogwerf, A. Michael Lincoff, Angel Rodriguez, Lei Chen, Yongming Qu> ;Cardiovascular Diabetology. 2016 May 17
• Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009-2011.
  Bae, J. P.,Lage, M. J.,Mo, D.,Nelson, D. R.,Hoogwerf, B. J.> ;J. Diabetes Complicat.. 2015 Dec 23
• Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions.
  Emons MF, Bae JP, Hoogwerf BJ, Kindermann SL, Taylor RJ, Nathanson BH> ;BMJ Open Diabetes Res Care. 2016-01-01
• 167 citations
  Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
  Michaela Diamant, Michael A. Nauck, Rimma M. Shaginian, James Malone, Simon Cleall, Matthew Reaney, Danielle de Vries, Byron J. Hoogwerf, Leigh MacConell, Bruce H. R. ...> ;Diabetes Care. 2014 Oct 1
• 3 citations
  Frederick C. Goetz, MD: A Profile of the Intersection Among Science, the Fine Arts, and Education
  Byron J. Hoogwerf, David M. Kendall, Elizabeth R. Seaquist> ;Diabetes Care. 2014 Sep 1
• 22 citations
  Effects of Exenatide on Kidney Function, Adverse Events, and Clinical End Points of Kidney Disease in Type 2 Diabetes
  Katherine R. Tuttle, Cory R. Heilmann, Byron J. Hoogwerf, Carl Brown, Pamela W. Anderson> ;American Journal of Kidney Diseases. 2013 Aug 1
• Join now to see all

Journal Articles

• Risk Factors for 30-Day Readmission Following Hypoglycemia-Related Emergency Room and Inpatient Admissions  
  Emons MF, Bae JP, Hoogwerf BJ, Kindermann SL, Taylor RJ, Nathanson BH, BMJ Open Diab Res Care, 1/1/2016
• Major Adverse Cardiovascular Events with Basal Insulin Peglispro versus Comparator Insulins in Patients with Type 1 or Type 2 Diabetes: a meta-analysis  
  Hoogwerf BJ, Lincoff AM, Rodriguez A, Chen L, Qu Y., Cardiovascular Diabetology., 1/1/2016
• Perspectives on some controversies in cardiovascular disease risk assessment in the pharmaceutical development of glucose lowering medications  
  Hoogwerf, BJ, Manner, DH, Fu, H, Moscarelli, E, Gaydos, BL, Heine, R, Diabetes Care, 1/1/2016
• Similar HbA1c Reduction and Hypoglycaemia with Variable- Vs Fixed-Time Dosing of Basal Insulin Peglispro (BIL) in Type 1 Diabetes: IMAGINE 7 Study  
  Garg S, MD, Selam J-L, MD, Bhargava A, Schloot N, Luo J, Zhang Q, Jacobson JG, Hoogwerf BJ., Diabetes Obes Metab, 1/1/2016
• Lipid Changes During Basal Insulin Peglispro, Insulin Glargine, or NPH Treatment in 6 IMAGINE Trials  
  Ginsberg H, Cariou B, Orchard TO, Chen L, Luo J, Bastyr III EJ, Bue-Valleskey J, Chang AM, Ivanyi T, Jacober SJ, Hoogwerf BJ., Diabetes Obes Metab, 1/1/2016
• Obesity and Glycemic Control in Patients with Diabetes Mellitus: Analysis of Physician Electronic Health Records in the US from 2009-2011  
  Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ, J of Diabetes and it Complications, 1/1/2015
• A Profile of the Intersection among Science, the Fine Arts and Education  
  Hoogwerf, BJ, Kendall, DK, Seaquist, ER Frederick C. Goetz, Diabetes Care, 1/1/2014
• Effects of Exenatide on Kidney Function, Adverse Events and Clinical Endpoints of Kidney Disease in Type 2 Diabetes  
  Tuttle KR, Heilmann C, Hoogwerf BJ, Brown C, Anderson PW., AJKD (research letter)., 1/1/2013
• Metabolic outcomes of matched patient populations initiating exenatide BID vs insulin glargine in an ambulatory care setting  
  Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, et al., Diabetes Obes Metab., 1/1/2012
• Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications  
  Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J., Postgrad Med., 1/1/2012
• Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide  
  Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J, Endocr Pract., 1/1/2012
• Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy  
  Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB., Int J Clin Pract, 1/1/2012
• Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other g...  
  Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, et al., Diabetes Care., 1/1/2011
• Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy  
  Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R., J Med Econ., 1/1/2011
• Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes  
  Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L., Cardiovasc Diabetol., 1/1/2011
• Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study  
  Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, et al., Cardiovasc Diabetol, 1/1/2010
• Renin-angiotensin system blockade and cardiovascular and renal protection  
  Hoogwerf BJ., Am J Cardiol., 1/1/2010
• The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study  
  Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ., Obesity (Silver Spring)., 1/1/2010
• Association of SF-36 with coronary artery disease risk factors and mortality: a PreCIS study  
  Zhang JP, Pozuelo L, Brennan DM, Hoar B, Hoogwerf BJ., Prev Cardiol., 1/1/2010
• Clinical utility of waist circumference in predicting all-cause mortality in a preventive cardiology clinic population: a PreCIS Database Study  
  Bajaj HS, Brennan DM, Hoogwerf BJ, Doshi KB, Kashyap SR., Obesity (Silver Spring)., 1/1/2009
• All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study  
  Doshi KB, Kashyap SR, Brennan DM, Hoar BM, Cho L, Hoogwerf BJ., Diabetes Obes Metab., 1/1/2009
• Cleveland Clinic cardiovascular intensive care unit insulin conversion protocol  
  Olansky L, Sam S, Lober C, Yared JP, Hoogwerf B, J Diabetes Sci Technol., 1/1/2009
• Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study  
  Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL., J Womens Health (Larchmt)., 1/1/2008
• Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreC...  
  Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ., Arthritis Rheum., 1/1/2008
• Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes  
  Nielsen LL, Okerson T, Holcombe J, Hoogwerf B., J Diabetes Sci Technol., 1/1/2008
• Join now to see all

Books/Book Chapters

• Rapid Review: USMLE Step 3 
  Chapter: Endocrinology 
  Page 248.0 - 283.0Newton, M, Hoogwerf, B.Editors: D.D.K. Rolston & C. Neilsen.Mosby Elsevier, Philadelphia2008
• Preventive Cardiology: Insights into the Prevention and Treatment of Cardiovascular Disease 
  Chapter: Diabetes Mellitus, Hyperinsulinemia and Coronary Artery Disease. 
  Page 113.0 - 144.0Hoogwerf, BJ.Editors: J M Foody.Humana Press, Totowa, NJEdition Seco,2006
• Inflammatory Diseases of Blood Vessels 
  Chapter: Dyslipidemia in Rheumatic Disorders 
  Page 767.0 - 780.0Hoogwerf, BJ, Danese R, Villa-Forte A.Editors: G. Hoffman & C. Weyand.Marcel Dekker, Inc., New York2001
• Preventive Cardiology: Strategies for Prevention and Treatment of Coronary Artery Disease 
  Chapter: Diabetes Mellitus, Hyperinsulinemia and Coronary Artery Disease 
  Page 177.0 - 142.0Hoogwerf BJEditors: J M Foody.Humana Press, Totowa, NJ2000
• Peripheral Vascular Diseases 
  Chapter: Diagnosis and Treatment of Lipid Disturbances 
  Page 166.0 - 188.0Olin JW, Cressman MD, Hoogwerf BJ, Weinstein CEEditors: J Young et al..Mosby, St. LouisEdition Seco,1996
• The High Risk Patient: Management of the Critically Ill 
  Chapter: The Diabetic Patient 
  Hoogwerf BJEditors: Edward Sivak, Tom Higgins and Adam Seiver.Williams and Wilkins, Meda, PA1995
• Clinical Cardiac Rehabilitation: a Cardiologists Guide 
  Chapter: Cardiac rehabilitation in the diabetic patient 
  Hoogwerf BJEditors: Pashkow FJ and Dafoe WA.Williams & Wilkins, Baltimore, Maryland1993
• Textbook of Peripheral Vascular Disease 
  Chapter: The Diagnosis and Treatment of Lipid Disturbances 
  Olin J, Cressman M, Hoogwerf BJ, Weinstein CEditors: Jess Young, et al..Edition 161.,1991
• Lipids and Women's Health 
  Chapter: Diabetes Mellitus in Women 
  Hoogwerf BJEditors: G. Redmond.Springer Verlag1990
• Lipids and Women's Health 
  Chapter: Dietary Treatment of Lipids and Lipoprotein Disorders 
  Hoogwerf BJEditors: G. Redmond.Springer VerlagEdition 160.,1990
• Join now to see all